Cancer patients may have an increased risk of developing second primary malignancies after immune checkpoint inhibitor therapy.

Study results suggest that “telemedicine represents a unique opportunity to reduce time and travel burdens for patients with cancer considering clinical trials,” according to researchers.

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

CAD may lead to an 8 percent increase in adenoma detection rate and 2 percent increase in detection rate of advanced colorectal neoplasia.

A study in patients with solid tumors found that CRBSI is significantly linked to mortality in patients with PICCs, whereas CRT and CRLC are not significant risk factors.

Researchers sought to evaluate preferences related to treatment features of BCMA-directed bispecific antibodies and CAR-T therapy.

Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...

Investigators from Canada and the UK conducted a systematic review and meta-analysis to update evidence associating eradication of Helicobacter pylori with reduced gastric cancer risk.

Virtual reality relaxation program can reduce pain intensity, with significant changes in brain functional connectivity patterns.

Nonpharmacologic interventions to ease pain and anxiety during bone marrow biopsy are feasible and easy to implement. In addition, they do not interfere ...

Barriers contributing to underreporting of fatigue also include belief that symptom is sign disease is progressing and attempt to be a “good patient.” ...